Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) 3-Year EBITDA Growth Rate : 22.50% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Anhui Wanbang Pharmaceutical Technology Co 3-Year EBITDA Growth Rate?

Anhui Wanbang Pharmaceutical Technology Co's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.49.

During the past 12 months, Anhui Wanbang Pharmaceutical Technology Co's average EBITDA Per Share Growth Rate was 10.10% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 22.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 27.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Anhui Wanbang Pharmaceutical Technology Co was 44.40% per year. The lowest was 22.50% per year. And the median was 29.70% per year.

Competitive Comparison of Anhui Wanbang Pharmaceutical Technology Co's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Anhui Wanbang Pharmaceutical Technology Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anhui Wanbang Pharmaceutical Technology Co's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anhui Wanbang Pharmaceutical Technology Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Anhui Wanbang Pharmaceutical Technology Co's 3-Year EBITDA Growth Rate falls into.

Anhui Wanbang Pharmaceutical Technology Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Anhui Wanbang Pharmaceutical Technology Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Anhui Wanbang Pharmaceutical Technology Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anhui Wanbang Pharmaceutical Technology Co Ltd (SZSE:301520) » Definitions » 3-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

southwest corner of the intersection of Mingzhu Avenue and Huolongdi Road, Building 1, Anhui Wanbang Pharmaceutical, High-tech Zone, Anhui, Hefei, CHN, 230000

Website

http://www.ahwbyy.cn

Anhui Wanbang Pharmaceutical Technology Co Ltd is a one-stop CRO service platform that engages in the entire process from pharmaceutical development to clinical research of innovative drugs, improved new drugs and generic drugs. It aims to provide drug research and development and clinical trials for drug launch, including pharmaceutical research, clinical services, biological sample analysis and testing, SMO services and data statistics and analysis.

Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) Headlines

No Headlines